9-month ABSORB data show no thrombosis for Abbott's stent

US health care major Abbott Laboratories reported positive results from ABSORB, the world's first clinical trial evaluating the safety and performance of a fully-bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease.

Nine-month results from the first 30 patients in the trial, presented at the 2007 EuroPCR meeting, held in Barcelona, Spain, demonstrated no stent thrombosis and a low (4.0% in one patient) rate of major adverse cardiac events, such as heart attack or repeat interventional medical treatment. The results confirm the six-month findings from ABSORB, which were announced in March, and show no new adverse events between six and nine months.

"These ABSORB nine-month data reaffirm the positive results we saw with Abbott's bioabsorbable stent system at six months," said ABSORB investigator Dariusz Dudek. "As we continue the ABSORB trial, we look forward to evaluating an updated version of the stent system designed to deliver additional support to the arterial wall and with the potential to reduce late vessel renarrowing even further," he added.